BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to FaDu cell line is 62
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | IF staining and Western Blotting followed by SFA | NA | 0.52 | 1 | 31399556 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 1 | 32708734 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Cisplatin | SP assay followed by Western Blotting and FACs | NA | 0.52 | 1 | 29228308 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by Western Blotting | NA | 0.52 | 1 | 34502158 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Cisplatin | SFA followed by qRT-PCR | NA | 0.52 | 1 | 32206093 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Irradiation | FACs | NA | 0.52 | 1 | 28844650 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by FACs | NA | 0.52 | 1 | 24874475 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | FACs | NA | 0.52 | 1 | 24201869 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA and FACs | NA | 0.52 | 1 | 27108536 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | IF staining and Western Blotting followed by SFA | NA | 0.52 | 0.7582 | 31399556 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.7582 | 32708734 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Cisplatin | SP assay followed by Western Blotting | NA | 0.52 | 0.7582 | 29228308 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR | NA | 0.52 | 0.7582 | 28093940 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA and FACs | NA | 0.52 | 0.7582 | 27108536 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.684 | 31382448 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Dasatinib | Western Blotting followed by qRT-PCR | NA | 0.48 | 0.684 | 31382448 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Saracatinib | Western Blotting followed by qRT-PCR | NA | 0.48 | 0.684 | 31382448 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | Western Blotting followed by SFA | NA | 0.48 | 0.684 | 31399556 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Cisplatin | SP assay followed by Western Blotting | NA | 0.48 | 0.684 | 29228308 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR | NA | 0.48 | 0.684 | 32708734 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Irradiation | ALDEFLUOR assay | NA | 0.48 | 0.684 | 28844650 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by ALDEFLUOR assay | NA | 0.48 | 0.684 | 34502158 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.5461 | 29228308 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Dasatinib | Western Blotting followed by qRT-PCR | NA | 0.48 | 0.5461 | 31382448 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Saracatinib | Western Blotting followed by qRT-PCR | NA | 0.48 | 0.5461 | 31382448 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | Western Blotting and SFA | NA | 0.48 | 0.5461 | 25871396 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 32206093 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 28093940 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 32708734 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.6448 | 29228308 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 32708734 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Dasatinib | Western Blotting followed by qRT-PCR | NA | 0.48 | 0.6448 | 31382448 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Saracatinib | Western Blotting followed by qRT-PCR | NA | 0.48 | 0.6448 | 31382448 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 34502158 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | Western Blotting and SFA | NA | 0.48 | 0.6448 | 25871396 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | Western Blotting followed by SFA | NA | 0.48 | 0.6448 | 31399556 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | Western Blotting | NA | 0.48 | 0.6448 | 24201869 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 32206093 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR | NA | 0.48 | 0.6448 | 28093940 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by FACs | NA | 0.48 | 0.6448 | 24874475 |
| RXRA | 10477 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.0021 | 29228308 |
| RXRA | 10477 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Cisplatin | Western Blotting | NA | 0.48 | 0.0021 | 29228308 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.5695 | 29228308 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.5695 | 31382448 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 34502158 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | Western Blotting and SFA | NA | 0.48 | 0.5695 | 25871396 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | Western Blotting followed by CFA | NA | 0.48 | 0.5695 | 34837170 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5695 | 32708734 |
| SHH | 10848 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Cisplatin | SFA followed by IF staining and qRT-PCR | NA | 0.44 | 0.0201 | 32206093 |
| HSPA5 | 5238 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | FACs followed by Western Blotting | NA | 0.4 | 0.0117 | 24201869 |
| ABCG2 | 74 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Cisplatin | SP assay followed by Western Blotting | NA | 0.28 | 0.1739 | 29228308 |
| STAT3 | 11364 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0223 | 34502158 |
| TAFAZZIN | 11577 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0011 | 31399556 |
| NFE2L2 | 7782 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Cisplatin | SFA followed by IF staining | NA | 0.24 | 0.0042 | 32206093 |
| CSPG4 | 2466 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0032 | 28093940 |
| GLI1 | 4317 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | Cisplatin | SFA followed by qRT-PCR | NA | 0.2 | 0.0308 | 32206093 |
| MYC | 7553 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR | NA | 0.2 | 0.1304 | 28093940 |
| NT5E | 8021 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0095 | 32708734 |
| SMO | 11119 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0212 | 28093940 |
| THY1 | 11801 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0371 | 32708734 |
| CD24 | 1645 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | FACs | NA | 0.12 | 0.456 | 24201869 |
| MME | 7154 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | FaDu | NA | SFA followed by FACs | NA | 0.12 | 0.0053 | 24874475 |